Research
Hormonal
GLP-1 receptor agonists (e.g., liraglutide) induce weight loss primarily by targeting brainstem circuits (specifically the area postrema) rather than mimicking natural gut signals, as natural GLP-1 levels do not regulate body weight.
GLP-1 drugs work by targeting the brainstem to reduce food intake, not by mimicking natural gut signals. This is a distinct mechanism from natural satiety.
GoodQualifiesHIGH confidence
Little evidence has linked gut- derived GLP- 1 to the normal control of body weight... Therefore, if GLP- 1 agonists are not mimicking a gut signal, one possibility is that the significant reduction in weight caused by these drugs is the result of direct targeting of the hypothalamus... However... the only place in the CNS that expresses GLP- 1 receptors in excitatory neurons... is in the area postrema (AP), located in the brainstem.
Why this rating
Supported by receptor deletion studies in mice.
Source
Physiology of Energy Intake in the Weight‐Reduced State
Hans‐Rudolf Berthoud et al. · Obesity · 2021
DOI 10.1002/oby.23080
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intentional weight loss triggers strong counterregulatory physiological responses, specifically increased hunger and reduced energy expenditure (hypometabolism), which actively defend the original body weight and facilitate rapid weight regain.Strong
- Bariatric surgery (specifically Roux-en-Y gastric bypass) can establish a new, lower body weight set point by altering gastrointestinal signals to the brainstem, thereby suppressing the counterregulatory hunger and hypometabolism typically seen after diet-induced weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →